Published in N Engl J Med on June 25, 1981
Economic evaluation and health care. What does it mean? BMJ (1993) 2.09
Cost-effectiveness analysis. BMJ (1993) 1.88
Complications of immobilization and bed rest. Part 1: Musculoskeletal and cardiovascular complications. Can Fam Physician (1993) 1.23
Impact of venography on the diagnosis and management of deep vein thrombosis. Br Med J (Clin Res Ed) (1983) 1.15
Diagnosis and treatment of venous thromboembolism by consultants in Scotland. Br Med J (Clin Res Ed) (1983) 1.14
Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. Can Med Assoc J (1982) 0.90
Emergency phlebography service: is it worth while? Br Med J (Clin Res Ed) (1987) 0.88
Noninvasive and venographic diagnosis of deep vein thrombosis. Cardiovasc Intervent Radiol (1988) 0.80
How to read clinical journals: VII. To understand an economic evaluation (part A). Can Med Assoc J (1984) 0.79
Multimodality imaging of the peripheral venous system. Int J Biomed Imaging (2007) 0.78
How to read clinical journals: VII. To understand an economic evaluation (part B). Can Med Assoc J (1984) 0.78
Computer-aided selection of diagnostic tests in jaundiced patients. Gut (1985) 0.75
Appropriate use of D-dimer testing can minimize over-utilization of venous duplex ultrasound in a contemporary high-volume hospital. Ann Vasc Surg (2014) 0.75
Influence of perfusion and ventilation scans on therapeutic decision making and outcome in cases of possible embolism. West J Med (1985) 0.75
The role of emergency venography in the diagnosis and management of deep venous thrombosis. Ulster Med J (1990) 0.75
Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines. Vasc Specialist Int (2016) 0.75
Evidence based medicine: what it is and what it isn't. BMJ (1996) 66.70
Inpatient general medicine is evidence based. A-Team, Nuffield Department of Clinical Medicine. Lancet (1995) 24.14
Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med (1991) 18.33
The Burlington randomized trial of the nurse practitioner. N Engl J Med (1974) 17.02
Bias in analytic research. J Chronic Dis (1979) 16.40
Contribution of adhesion to bacterial persistence in the mouse urinary tract. Infect Immun (1983) 14.71
A controlled trial of teaching critical appraisal of the clinical literature to medical students. JAMA (1987) 14.20
The number needed to treat: a clinically useful measure of treatment effect. BMJ (1995) 13.89
An assessment of clinically useful measures of the consequences of treatment. N Engl J Med (1988) 13.02
Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med (1998) 11.27
Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med (1978) 9.29
Controversy in the detection of disease. Lancet (1975) 7.85
How to keep up with the medical literature: V. Access by personal computer to the medical literature. Ann Intern Med (1986) 7.36
Controversy in counting and attributing events in clinical trials. N Engl J Med (1979) 7.25
Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet (1975) 7.22
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86
Users' guides to the medical literature. I. How to get started. The Evidence-Based Medicine Working Group. JAMA (1993) 6.83
A utility maximization model for evaluation of health care programs. Health Serv Res (1972) 6.67
Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem (1997) 5.51
Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA (1995) 5.28
Problems in the handling of clinical and research evidence by medical practitioners. Arch Intern Med (1983) 5.16
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Management of anticoagulation before and after elective surgery. N Engl J Med (1997) 5.10
A randomized trial of continuing medical education. N Engl J Med (1982) 4.95
Improvement of medication compliance in uncontrolled hypertension. Lancet (1976) 4.84
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med (1996) 4.70
Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med (1997) 4.47
A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol (2001) 4.39
The Burlington randomized trial of the nurse practitioner: health outcomes of patients. Ann Intern Med (1974) 4.37
Genetics of digalactoside-binding adhesin from a uropathogenic Escherichia coli strain. Infect Immun (1983) 4.03
A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med (1993) 3.67
The utility of different health states as perceived by the general public. J Chronic Dis (1978) 3.65
A new type of cardioselective adrenoceptive blocking drug. Br J Pharmacol (1973) 3.65
The Drosophila ninaE gene encodes an opsin. Cell (1985) 3.65
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Inhibition of experimental ascending urinary tract infection by an epithelial cell-surface receptor analogue. Nature (1982) 3.50
Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet (2000) 3.50
An empirical demonstration of Berkson's bias. J Chronic Dis (1978) 3.48
Accuracy of clinical assessment of deep-vein thrombosis. Lancet (1995) 3.45
Limitations of impedance plethysmography in the diagnosis of clinically suspected deep-vein thrombosis. Ann Intern Med (1993) 3.40
Molecular cloning and physical characterization of a chromosomal hemolysin from Escherichia coli. Infect Immun (1983) 3.30
Can simple clinical measurements detect patient noncompliance? Hypertension (1981) 3.29
Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation (1996) 3.23
Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest (1986) 3.16
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med (1982) 3.16
Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med (1998) 3.09
The cloned dopa decarboxylase gene is developmentally regulated when reintegrated into the Drosophila genome. Cell (1983) 3.08
p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol (2000) 3.05
Does a mailed continuing education program improve physician performance? Results of a randomized trial in antihypertensive care. JAMA (1986) 3.04
Choosing the best research design for each question. BMJ (1998) 3.03
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med (1986) 3.00
The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions. J Chronic Dis (1985) 2.96
How to keep up with the medical literature: I. Why try to keep up and how to get started. Ann Intern Med (1986) 2.94
Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med (1979) 2.91
Quality-of-care appraisal in primary care: a quantitative method. Ann Intern Med (1975) 2.87
Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest (1992) 2.81
A re-examination of the meaning and importance of supplier-induced demand. J Health Econ (1994) 2.78
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1992) 2.76
Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosomes Cancer (2000) 2.73
Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis. J Clin Epidemiol (1995) 2.73
A standard heparin nomogram for the management of heparin therapy. Arch Intern Med (1991) 2.69
Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation (1996) 2.69
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med (1990) 2.63
A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med (1972) 2.60
The development and application of indices of health: general methods and a summary of results. Am J Public Health (1977) 2.53
Clinical recommendations using levels of evidence for antithrombotic agents. Chest (1995) 2.52
Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med (1998) 2.49
Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet (1988) 2.44
Using research findings in clinical practice. BMJ (1998) 2.40
The rational clinical examination. Does this patient have a clinically important carotid bruit? JAMA (1993) 2.38
The rational clinical examination. Does this patient have splenomegaly? JAMA (1993) 2.38
Hypertension in a family practice. Can Med Assoc J (1977) 2.36
Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice. Infect Immun (1984) 2.35
Establishing a therapeutic range for heparin therapy. Ann Intern Med (1993) 2.31
Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med (1989) 2.28
Managing oral anticoagulant therapy. Chest (2001) 2.25
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Retroid virus genome replication. Adv Virus Res (1987) 2.23
Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med (1992) 2.23
Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med (1973) 2.17
The Dr hemagglutinin, afimbrial adhesins AFA-I and AFA-III, and F1845 fimbriae of uropathogenic and diarrhea-associated Escherichia coli belong to a family of hemagglutinins with Dr receptor recognition. Infect Immun (1990) 2.14
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest (1990) 2.14
Rules of evidence and clinical recommendations for the management of patients. Can J Cardiol (1993) 2.11
When was a "negative" clinical trial big enough? How many patients you needed depends on what you found. Arch Intern Med (1985) 2.11
Transferring evidence from research into practice: 1. The role of clinical care research evidence in clinical decisions. ACP J Club (1996) 2.10
Dynamic microscopy of nanoscale cluster growth at the solid-liquid interface. Nat Mater (2003) 2.07
Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost (2015) 2.07
Guidelines for managing raised blood pressure. BMJ (1996) 2.03